Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis
Table 1
Characteristics of the patients.
Characteristics
Total (n = 19)
Age (years), mean (SD)
37.9 (12.0)
Sex, n (%)
Male
19 (100)
EASI, mean (SD)
36.9 (15.1)
IGA, mean (SD)
3.3 (0.5)
POEM, mean (SD)
16.6 (7.0)
DLQI, mean (SD)
12.2 (7.3)
TARC (pg/mL), mean (SD)
4,256.5 (4013.3)
Eosinophil (/µL), mean (SD)
773.9 (660.4)
LDH (IU/L), mean (SD)
323.9 (102.2)
IgE (IU/mL), mean (SD)
13,150.7 (25030.4)
Allergic comorbidity, n (%)
Rhinitis
9 (47)
Asthma
3 (16)
Conjunctivitis
2 (11)
Note. SD: standard deviation; EASI: Eczema Area and Severity Index; IGA: Investigator’s Global Assessment; POEM: Patient-Oriented Eczema Measure; DLQI: Dermatology Life Quality Index; TARC: thymus and activation-regulated chemokine.